These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 10807189)

  • 1. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.
    van Praag RM; Prins JM; Roos MT; Schellekens PT; Ten Berge IJ; Yong SL; Schuitemaker H; Eerenberg AJ; Jurriaans S; de Wolf F; Fox CH; Goudsmit J; Miedema F; Lange JM
    J Clin Immunol; 2001 May; 21(3):218-26. PubMed ID: 11403229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.
    Prins JM; Jurriaans S; van Praag RM; Blaak H; van Rij R; Schellekens PT; ten Berge IJ; Yong SL; Fox CH; Roos MT; de Wolf F; Goudsmit J; Schuitemaker H; Lange JM
    AIDS; 1999 Dec; 13(17):2405-10. PubMed ID: 10597782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.
    Depincé-Berger AE; Vergnon-Miszczycha D; Girard A; Frésard A; Botelho-Nevers E; Lambert C; Del Tedesco E; Genin C; Pozzetto B; Lucht F; Roblin X; Bourlet T; Paul S
    Retrovirology; 2016 Jun; 13(1):44. PubMed ID: 27363286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
    Davey RT; Bhat N; Yoder C; Chun TW; Metcalf JA; Dewar R; Natarajan V; Lempicki RA; Adelsberger JW; Miller KD; Kovacs JA; Polis MA; Walker RE; Falloon J; Masur H; Gee D; Baseler M; Dimitrov DS; Fauci AS; Lane HC
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15109-14. PubMed ID: 10611346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
    Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
    AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
    Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
    AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
    Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS
    Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
    Finzi D; Hermankova M; Pierson T; Carruth LM; Buck C; Chaisson RE; Quinn TC; Chadwick K; Margolick J; Brookmeyer R; Gallant J; Markowitz M; Ho DD; Richman DD; Siliciano RF
    Science; 1997 Nov; 278(5341):1295-300. PubMed ID: 9360927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).
    Hazenberg MD; Stuart JW; Otto SA; Borleffs JC; Boucher CA; de Boer RJ; Miedema F; Hamann D
    Blood; 2000 Jan; 95(1):249-55. PubMed ID: 10607709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
    Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
    J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV type 1-reactive chemokine-producing CD8+ and CD4+ cells expanded from infected lymph nodes.
    Triozzi PL; Bresler HS; Aldrich WA
    AIDS Res Hum Retroviruses; 1998 May; 14(8):643-9. PubMed ID: 9618075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
    Autran B; Carcelain G; Li TS; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
    Science; 1997 Jul; 277(5322):112-6. PubMed ID: 9204894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
    Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A
    AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.